Free Trial

Black Diamond Therapeutics (BDTX) Earnings Date, Estimates & Call Transcripts

Black Diamond Therapeutics logo
$2.40 +0.12 (+5.26%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$2.42 +0.02 (+0.67%)
As of 08/8/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Black Diamond Therapeutics Earnings Summary

Black Diamond Therapeutics issued Q2 2025 earnings on August 7, 2025, reporting an EPS of -$0.19, which beat the consensus estimate of -$0.25 by $0.06. With a trailing EPS of $0.06 and a P/E Ratio of 10.44, Black Diamond Therapeutics' earnings are expected to grow next year, from ($1.30) to ($1.22) per share.

Latest Q2
Earnings Date
Aug. 7Estimated
Consensus EPS
(Aug. 7)
-$0.25
Actual EPS
(Aug. 7)
-$0.19 Beat By $0.06

Q2 2025 Earnings Resources

Get Black Diamond Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Diamond Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

BDTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Black Diamond Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20252-$0.32$0.92$0.30
Q2 20252-$0.33-$0.25-$0.29
Q3 20252-$0.33-$0.25-$0.29
Q4 20252-$0.34-$0.19-$0.27
FY 2025 8 -$1.32 $0.23 -$0.55
Q1 20261-$0.22-$0.22-$0.22
Q2 20261-$0.23-$0.23-$0.23
Q3 20261-$0.23-$0.23-$0.23
Q4 20261-$0.24-$0.24-$0.24

Black Diamond Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025-$0.25-$0.19+$0.06-$0.19--
3/6/2025Q4 2024-$0.31-$0.28+$0.03-$0.28--
11/5/2024--$0.37-$0.28+$0.09-$0.28--
8/6/2024Q2 2024-$0.39-$0.36+$0.03-$0.36--
5/9/2024Q1 2024-$0.44-$0.35+$0.09-$0.35--
3/12/2024Q4 2023-$0.47-$0.34+$0.13-$0.34--
11/6/2023Q3 2023-$0.49-$0.45+$0.04-$0.45--
8/11/2023Q2 2023-$0.54-$0.52+$0.02-$0.52--

Black Diamond Therapeutics Earnings - Frequently Asked Questions

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earning data on Thursday, August 7, 2025. Learn more on BDTX's earnings history.

In the previous quarter, Black Diamond Therapeutics (NASDAQ:BDTX) reported ($0.19) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.25) by $0.06. Learn more on analysts' earnings estimate vs. BDTX's actual earnings.

Black Diamond Therapeutics' earnings report can be found in their filing with the SEC.
View SEC filing

Black Diamond Therapeutics (NASDAQ:BDTX) has a recorded net income of -$69.68 million. BDTX has generated $0.06 earnings per share over the last four quarters.

Black Diamond Therapeutics (NASDAQ:BDTX) has a trailing price-to-earnings ratio of 10.44.

Black Diamond Therapeutics' earnings are expected to grow from ($1.30) per share to ($1.22) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:BDTX) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners